BR9916043A - Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes - Google Patents

Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes

Info

Publication number
BR9916043A
BR9916043A BR9916043-9A BR9916043A BR9916043A BR 9916043 A BR9916043 A BR 9916043A BR 9916043 A BR9916043 A BR 9916043A BR 9916043 A BR9916043 A BR 9916043A
Authority
BR
Brazil
Prior art keywords
patients
compound
treatment
pharmaceutical composition
same
Prior art date
Application number
BR9916043-9A
Other languages
English (en)
Inventor
Jonathan David Bloom
Kevin Joseph Curran
Martin Josephdigrandi
Russell George Dushin
Thomas Richard Jones
Stanleyalbert Lang
Adma Antonia Ross
Eugene Anthony Terefenko
Rian Mark O'hara
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of BR9916043A publication Critical patent/BR9916043A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/20—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/22—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Abstract

"COMPOSTO, USO DO MESMO E DE SEUS SAISFARMACêUTICAMENTE ACEITáVEIS E, COMPOSIçãOFARMACêUTICA PARA TRATAMENTO DE INFECçõES DEHERPES VIRAL EM PACIENTES". A presente invenção refere-sea compostos poliaromáticos tendo atividade antiviral útil contravírus da família do herpes, a uma composição que os contém, e aum processo de usá-los para o tratamento de infecções de vírusde herpes.
BR9916043-9A 1998-12-09 1999-12-06 Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes BR9916043A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20816498A 1998-12-09 1998-12-09
PCT/US1999/028916 WO2000034261A2 (en) 1998-12-09 1999-12-06 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group

Publications (1)

Publication Number Publication Date
BR9916043A true BR9916043A (pt) 2001-12-04

Family

ID=22773466

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916043-9A BR9916043A (pt) 1998-12-09 1999-12-06 Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes

Country Status (14)

Country Link
EP (1) EP1144399A3 (pt)
JP (1) JP2002533301A (pt)
KR (1) KR20010086091A (pt)
CN (1) CN1367785A (pt)
AU (1) AU2353900A (pt)
BR (1) BR9916043A (pt)
CA (1) CA2351690A1 (pt)
CZ (1) CZ20012063A3 (pt)
EA (1) EA200100639A1 (pt)
HU (1) HUP0203405A2 (pt)
IL (1) IL143263A0 (pt)
NO (1) NO20012835L (pt)
WO (1) WO2000034261A2 (pt)
ZA (1) ZA200104322B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
DE60115394T2 (de) 2000-02-29 2006-10-19 Millennium Pharmaceuticals, Inc., Cambridge Benzamide und ähnliche inhibitoren vom faktor xa
NZ544674A (en) * 2003-07-10 2009-03-31 Achillion Pharmaceuticals Inc Substituted arylthiourea derivatives useful as inhibitors of viral replication
DE102004015007A1 (de) * 2004-03-26 2005-10-13 Bayer Healthcare Ag Substituierte Imidazole
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
DE102005008183A1 (de) 2005-02-23 2006-08-31 Bayer Healthcare Ag Heterocyclylamid-substituierte Imidazole
CA2667488C (en) 2006-11-02 2015-07-07 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
US9284310B2 (en) 2012-11-03 2016-03-15 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
WO2014070979A1 (en) * 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
CN112807294B (zh) * 2019-11-18 2023-09-05 武汉大学 一种酰基硫脲类化合物在制备治疗或预防单纯疱疹病毒i型感染药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE298741T1 (de) * 1997-04-10 2005-07-15 Pharmacia & Upjohn Co Llc Polyaromatische verbindungen zur behandlung von herpes-infektionen

Also Published As

Publication number Publication date
IL143263A0 (en) 2002-04-21
CZ20012063A3 (cs) 2001-10-17
AU2353900A (en) 2000-06-26
JP2002533301A (ja) 2002-10-08
CN1367785A (zh) 2002-09-04
EP1144399A2 (en) 2001-10-17
HUP0203405A2 (hu) 2003-02-28
NO20012835D0 (no) 2001-06-08
CA2351690A1 (en) 2000-06-15
KR20010086091A (ko) 2001-09-07
EP1144399A3 (en) 2002-09-11
WO2000034261A2 (en) 2000-06-15
ZA200104322B (en) 2002-10-25
WO2000034261A3 (en) 2002-01-31
EA200100639A1 (ru) 2002-06-27
NO20012835L (no) 2001-07-19

Similar Documents

Publication Publication Date Title
BR9810745A (pt) Derivados de benzimidazol
BR0008840A (pt) Derivados de camptotecina tendo atividade antitumoral
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
DK0973735T3 (da) Polyaromatiske antivirale præparater
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
YU7296A (sh) Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
PT741577E (pt) Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
PT100199A (pt) Combinacao antiviral de nucleosidos e processo para a sua preparacao
BR9909474A (pt) Formas ii, cristalina e v de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, solvato de etanol de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento de uma infecção viral em um humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol
BR9506581A (pt) Composto composição farmacêutica uso do composto processo para a profilaxia ou tratamento de uma condição clínica em um manífero por exemplo um humano e para a preparação de um composto e composto intermediário
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
BR9910071A (pt) Composição farmacêutica, processos para aumentar e manter a homogeneidade de uma composição farmacêutica e para tratar, reverter, reduzir ou inibir infecções retrovirais, uso de abacavir, lamivudina, zidovudina ou de um derivado farmaceuticamente aceitável dos mesmos, e de um agente de deslizamento farmaceuticamente aceitável, artigo de manufatura, e, processo para a preparação de uma composição farmacêutica
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
DK178188D0 (da) Antivirusmiddel
BR9706938A (pt) Composto uso do mesmo formulação farmacêutica e processos para produzir o composto e para o tratamento ou a prevenção de sintomas ou efeitos de uma infecção virótica em um mamífero infectado incluindo um humano
BR9712614A (pt) Composição farmacêutica,processos para aumentar e manter a homogeneidade de uma composição farmac&eutica,para tratar,reverter,reduzir ou inibir infeccões retrovirais e para preparação de uma composição farmacêutica,uso de lamivudina ou de um derivado farmaceuticamenete aceitável da mesma,de zidovudina,ou de um derivado farmaceuticamente aceitável da mesma e de um agente de deslizamento farmaceuticamente aceitável,e, artigo de amnufatura.
BR9407862A (pt) Composto de flavina flavina derivado de flavina ou uma mistura que compreende duas ou mais destas composiçao farmacêutica e processo para o tratamento por profilaxia ou terapia de doença causada por infecçao virótica
BR9910185A (pt) Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana
ES2128353T3 (es) Composicion topica que contiene penciclovir.
BR9808305A (pt) Forma hidratada cristalina, processo para a preparação da forma hidratada cristalina, composição farmacêutica, processo de tratamento de um mamìfero, e, processo de tratamento ou de prevenção de dor.
MX9303985A (es) Nucleosidos terapeuticos.
BR9405308A (pt) Uso de um antagonista de bradicinina ou de um de seus sais fisiologicamente tolerados; preparado combinado; uso de um antagonista de bradicinina e de um outro agente antiviral, e processo para a preparação do dito preparado

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]